title: Obtaining the optimal treatment outcome with tazarotene.
abstract: Tazarotene topical gel (Tazorac) is a vitamin A derivative and the first topical retinoid to demonstrate therapeutic success in treating plaque-type psoriasis. It has been available in the United States since 1997. Tazarotene offers long-term remission in many patients and may be used in combination with corticosteroids and UVB therapy for even better results. Due to its potency as a vitamin derivative, tazarotene is also associated with irritation in some patients. Patients must be educated about proper application of the drug and realistic expectations for treatment outcome.
authors.affiliation: University of California-San Francisco, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: McClelland
mesh_terms: D003879:Dermatologic Agents / Q000627:therapeutic use*; D005782:Gels; D006801:Humans; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010353:Patient Education as Topic; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012176:Retinoids / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D005782:Gels; D009539:Nicotinic Acids; D012176:Retinoids; C086827:tazarotene